Core Viewpoint - OraSure Technologies, Inc. is facing a board election challenge as Altai Capital has nominated two candidates, including its founder Rishi Bajaj, for the Board of Directors at the upcoming 2026 Annual Meeting of Stockholders [1]. Group 1: Board Composition and Engagement - OraSure's Board has engaged extensively with Altai Capital, interviewing Mr. Bajaj for a potential board position but ultimately selecting an alternative candidate [2]. - The Board emphasizes its strong, independent, and engaged composition, having refreshed significantly since 2022 with seven directors departing and three new independent directors added, including healthcare investor Steven K. Boyd [3]. Group 2: Nominations and Proxy Statement - The Nominating and Corporate Governance Committee, along with OraSure's Board, will review Altai's nominations and will present their recommendations in a definitive proxy statement to be filed with the SEC [4]. - Shareholders are not required to take any action at this time regarding the nominations [4]. Group 3: Company Overview - OraSure Technologies, Inc. specializes in point-of-need and home diagnostic tests, aiming to improve healthcare access, quality, and value through innovative testing and sample management solutions [6]. - The company operates globally, providing products to various sectors including clinical laboratories, hospitals, and direct consumers [6].

Investment Highlights - OraSure Technologies (OTI) is positioned to return to growth in its core business in 2025[5] - OTI has a differentiated product pipeline aligned with long-term healthcare trends, with potential product milestones expected to accelerate growth in 2025 and beyond[5] - OTI has an opportunity for significant operating margin leverage as volumes grow[5] - As of Q3 2024, OTI has $279 million of cash and no debt[5, 37] Strategic Transformation - OTI is focused on strengthening its foundation, elevating core growth, and accelerating profitable growth[7, 42] - OTI aims to improve access, quality, and value of healthcare with innovation in effortless tests and sample management solutions[9] - OTI is expanding its diagnostics portfolio with new tests and next-generation platform expansion, prioritizing instrument-free tests[12, 13] - OTI's acquisition of Sherlock Biosciences strengthens and broadens its diagnostic portfolio with molecular testing capabilities[19] - OTI anticipates submitting Sherlock's disposable self-test for CT/NG to the FDA by the end of 2025, targeting a $1.5 billion and growing market[22] Financial Performance - OTI is targeting a path to 50% adjusted gross margin[40] - The company's non-GAAP gross margin was 40% in FY23 and an estimated 40% in FY24[38] - Core revenue was $143 million in FY23 and an estimated $138 million in FY24, while COVID-19 revenue was $115 million in FY23 and an estimated $45 million in FY24[38]

Core Viewpoint - OraSure Technologies, Inc. has authorized a stock repurchase program of up to $40 million over the next twenty-four months, to be funded from cash on hand [1][2]. Company Overview - OraSure Technologies, Inc. is a leader in point-of-need and home diagnostic tests and sample management solutions, aiming to improve access, quality, and value of healthcare through innovative testing and sample management [3]. - The company, along with its subsidiaries DNA Genotek Inc. and Sherlock Biosciences, Inc., develops, manufactures, and distributes rapid diagnostic tests and sample collection devices globally [3]. Stock Repurchase Program - The stock repurchase may be executed through various methods in compliance with applicable laws, with the timing and amount determined at the management's discretion [2]. - The repurchase program can be modified, suspended, or discontinued at any time without prior notice [2].